A B S T R A C T We tested the effects of nifedipine, a calcium antagonist, on atherogenesis in rabbits fed a 2% cholesterol diet. The drug was given orally, 40 mg/dl, and control rabbits received placebo. Nifedipine was well tolerated, and evoked only transient, moderate reductions in arterial pressure. Plasma total cholesterol after 8 wk before killing the rabbits was similar in the placebo and nifedipine-treated groups, averaging 1,903+138 (n = 13) and 1,848+121 mg/dl (n = 13; mean+SE; P > 0.8). In placebo-treated rabbits, aortic lesions stainable with Sudan IV covered 40±5% of the intimal surface, and the cholesterol concentration in aortic tissue was 47±5 mg/g protein.
INTRODUCTION
Current evidence suggests that calcium may play a pathogenic role in atherosclerosis (1) (2) (3) (4) (5) (6) (7) . In cholesterolfed rabbits, anticalcifying and hypocalcemic agents such as diphosphonates (2) (3) (4) (5) , thiophene compounds (6) , and EDTA (7) have been demonstrated to exert antiatherogenic effects without reducing the dietinduced hypercholesterolemia. In this report, we show that nifedipine suppresses atherogenesis in choles-terol-fed rabbits. Nifedipine and other calcium antagonists inhibit calcium entry into smooth muscle cells, but have no anticalcifying or hypocalcemic effects (8) . Results suggest that intracellular accumulation of calcium, a postulated nonspecific mechanism of cell death (9, 10) , may be important in mediating hypercholesterolemic vascular injury. METHODS 56 male white New Zealand rabbits from a single vendor (Boswell's Bunny Farm, Pacific, Mo.) weighing 2.3-2.6 kg were housed individually under controlled conditions and randomly assigned to four equal diet and treatment groups: (a) standard pellets and placebo, (b) standard pellets and nifedipine, (c) 2% cholesterol pellets (Nutritional Biochemicals, Cleveland, Ohio) and placebo, and (d) 2% cholesterol pellets and nifedipine. The daily amount of pellets was 100 g for all rabbits, and water was given ad lib. Nifedipine was force-fed, two 10-mg capsules at 7 a.m. and 7 p.m. (40 mg/d), and untreated rabbits received identical capsules without nifedipine (placebo). In each group, five rabbits were selected randomly for the study of arterial pressure during the first and last week of the diet period. A No. 21 pediatric needle was inserted into the central ear artery and taped to the ear (11) . Without restraining the rabbit, the needle was intermittently connected to a Gould P23 Db pressure transducer (Gould Inc., Instruments Div., Cleveland, Ohio), which was placed at mid-chest level and attached to a Gould amplifier/recorder system. At the beginning and at the end of the diet period, blood samples were collected from the central ear artery ofall rabbits into tubes containing Na2 EDTA (1 ,ug/100 ,ul). The samples were used for the determination of the microhematocrit, and the separated plasma was analyzed for total cholesterol, triglycerides, phosphate, total protein, and albumin with a Gemini automatic analyzer (Electro-Nucleonics, Inc., Fairfield, N. J.). Plasma calcium was measured by atomic absorption spectrophotometry (see below). The rabbits were killed after 8 wk. The thoracic aorta J. Clin. Invest. © The American Society for Clinical Investigation, Inc. * 0021-9738/81/11/1366/04 $1.00
Volume 68 November 1981 1366-1369 was removed, cleaned of surrounding tissue, and halved with longitudinal cuts through the anterior and posterior walls. Each longitudinal half-aorta was blotted and weighed. Onehalf was quickly frozen and stored at -70°C, the other laid flat, intimal side up, on clear plexiglas. The preparation was glued at its edges to the plastic with Permabond 910 (Permabond International Corp., Englewood, N. J.), and stained with Sudan IV (Sigma Chemical Co., St. Louis, Mo.) as described by Holmann et al. (4, 6, 12) . A plexiglas plate covered with translucent paper was placed on the surface of the preparation. The transparent outlines and stained areas of the vessel were delineated with black ink and areas planimetered with a computerized planimeter (model 9874 A Hewlett-Packard Co., Palo Alto, Calif.). The frozen half-aorta was pulverized at liquid nitrogen temperature, and homogenized in 10 ml of chloroform-methanol (2:1, vol/vol) in a Duall homogenizer (Kontes Co., Vineland, N. J.). Fractions of homogenate were dried and used for measurements ofcalcium by atomic absorption spectrophotometry on a Perkin-Elmer model 303 apparatus (Perkin-Elmer Corp., Physical Electronics Div., Eden Prairie, Minn.) as previously described (13), and for estimation of protein by the method of Lowry (14) . The rest of the homogenate was extracted as described by Chan et al. (6) for measurement of total cholesterol by the ferric chloride reaction (15) . Small weighed tissue samples from selected arteries were fixed in 10% buffered formalin, embedded in paraffin, and stained with hematoxylin-eosin or Verhoeff-van Gieson stain. The difference between sequential mean values in the same group was evaluated by the t test for paired comparisons. The difference between mean values for planimetered lesions was analyzed by Wilcoxon's signed rank test. Values relating lesions to tissue cholesterol were assessed by the same test. Differences between group means for variables occurring in all groups were evaluated by computerized analysis of variance using the General Linear Models procedure (16) .
RESULTS
Two cholesterol-fed rabbits, one receiving placebo, the other nifedipine, died of unknown cause during the diet period. Values for body weight, hematocrit, and biochemical measurements in plasma are summarized in Table I . Plasma cholesterol and triglyceride levels in cholesterol-fed rabbits given placebo or nifedipine were similar.
Effects of nifedipine and placebo on mean arterial pressure and heart rate during the 1st wk of cholesterol feeding are shown in Fig. 1 . After each dose of nifedipine, mean arterial pressure decreased maximally by 10-12 mm Hg (P < 0.001), and returned to control values within <2 h. Responses in the same rabbits at the end of the diet period were not significantly different from those elicited during the 1st wk (P > 0.5), and values in control rabbits given nifedipine or placebo did not differ from those obtained in cholesterol-fed rabbits receiving the corresponding treatment (P > 0.5 for all values).
In cholesterol-fed rabbits, the percentage of the intimal surface covered by Sudan-positive lesions averaged 40±5% (SE) in placebo-treated rabbits (n = 13), and 17±3% in nifedipine-treated rabbits (n = 13; P < 0.001). The cholesterol concentrations in aortas from rabbits given standard pellets were 6.1+0.3 mg/g protein for the placebo group, and 6.3+0.4 mg/g protein for the nifedipine group. In cholesterol-fed rabbits, values for the placebo and nifedipine groups differed significantly (P < 0.001), averaging 47±5 and 29±2 mg/g protein. Treatment with nifedipine altered the relationship between aortic cholesterol accumulation and formation of Sudan-positive lesions. The ratio relating planimetered lesions (percent) to tissue cholesterol (milligrams per gram protein) averaged 0.85±0.05 and 0.58±0.04%/(mg/g protein) in untreated and treated rabbits (P < 0.001). In rabbits given standard diet, calcium concentrations in aortic tissue for the placebo and nifedipine groups were 190±11 and 194±14 ,ug/g protein. In cholesterol-fed rabbits, aortic calcium for the nifedipine group was significantly lower than that for the placebo group, values averaging 202±14 and 297±18 ug/g protein (P < 0.005). Microscopic evaluation of aortic tissue revealed qualitatively similar lesions in the two cholesterol-fed groups, but a quantitative structural analysis was not performed in this study.
DISCUSSION
Calcium overload as a pathogenic mechanism of cell injury has been incriminated in various disorders of cardiac and skeletal muscle including catecholamineinduced cardiac necrosis (8, 13) , myocardial ischemia (8, 13) , myopathies (9, 17) , and malignant hyperthermia (18) . Of interest is that in the majority of these pathophysiological entities calcium antagonists effectively suppress calcium accumulation and cell necrosis (8, 13, 17, 18) . Moreover, myopathic Syrian hamsters given a calcium-deficient diet exhibit fewer lesions in skeletal and cardiac muscle (17) . Conversely, facilitation of calcium uptake with ionophores or membrane-active toxins such as lysophospholipids or macrolide antibiotics accelerate necrosis of isolated skeletal muscle (19) and rat hepatocytes in culture (10) .
Studies showing protective effects of calcium antagonists in syndromes associated with membrane injury, calcium overload, and cell necrosis may partly explain the antiatherogenic activity of nifedipine. Atherogenesis is accompanied by an accumulation of calcium in arterial walls (1) (2) (3) (4) (5) (6) (7) , and proliferation of smooth muscle cells, a key process in lesion formation, goes hand in hand with cell necrosis (20, 21) . Necrosis offoam cells releasing membrane-active lipid, such as cholesterol, may affect the membranes of neighboring cells and accelerate cellular deterioration and turnover. Decreased necrosis associated with intracellular retention of lipid may explain why lesion formation for a given lipid accumulation was significantly decreased in nifedipine-treated rabbits. We have previously demonstrated that a high cholesterol environment sensitizes isolated arteries to the constrictor effects of calcium, consistent with increased calcium uptake after acquisition of membrane cholesterol (22, 23) .
Although nifedipine may influence proliferating smooth muscle, the drug may act by other mechanisms. Arterial pressure is an important determinant of atherogenesis, and elevated pressure aggravates atherosclerosis in cholesterol-fed rabbits (11) . Therefore, vasodilator-induced hypotension might exert protective effects, although hypotensive responses were not sustained in this study. Moreover, potent vasodilators such as nifedipine might influence arteries by increasing vasa vasorum flow (24) . Calcium antagonists may act on platelets. However, nifedipine does not appear to have antiaggregating effects on human platelets (25, 26) , and the action of verapamil and diltiazem on platelets occur only at high concentrations known to exert nonspecific effects (8, 26, 27) .
Since calcium antagonists are used extensively for the treatment of coronary artery disease (8) , the present study has potential clinical implications. Unlike anticalcifying drugs (2-7), calcium antagonists are not known to affect bone mineralization, and might be evaluated in children with familial hypercholesterolemia.
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